CLVLY Company Profile and Key Details

Q: Who are the executives of CLVLY?

Mr. Darren M. KeamyChief Financial Officer & Company Sec.Mr. Malcolm BullHead of Investor RelationsMr. Lachlan HayDirector of Global OperationsDr. Dennis J. WrightChief Scientific OfficerDr. Philippe Jacques Wolgen M.B.A., M.D., MBAChief Executive Officer, MD & Director

OTC : CLVLY

Clinuvel Pharmaceuticals

$7.36

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Clinuvel Pharmaceuticals Limited (CLVLY) stock remained unchanged at $7.36 a share on OTC. The stock opened at $6.98, fluctuating between $6.98 to $7.40 during the session.

Stock Snapshot

7.36

Prev. Close

371.02M

Market Cap

6.98

Day Low

P/E Ratio

0.46

EPS (TTM)

0.72

Cash Flow per Share

6.98

Open

50.41M

Number of Shares

7.4

Day High

82.77%

Free Float in %

3.56

Book Value

3.77K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 17, 2026	6.98	7.40	6.98	7.36	5.31K
Jun 16, 2026	7.15	7.25	6.85	6.92	11.31K
Jun 15, 2026	6.25	6.94	6.25	6.94	3.96K
Jun 12, 2026	6.62	6.62	6.26	6.26	429
Jun 11, 2026	6.20	6.20	6.20	6.20	566
Jun 10, 2026	6.34	6.34	6.19	6.19	1.3K
Jun 09, 2026	6.50	6.50	6.36	6.36	3.31K
Jun 08, 2026	6.60	6.73	6.59	6.73	1.82K
Jun 05, 2026	6.67	6.67	6.50	6.60	1.36K
Jun 04, 2026	6.55	6.55	6.37	6.37	2K
Jun 03, 2026	6.40	6.40	6.40	6.40	515
Jun 01, 2026	6.75	6.95	6.75	6.95	2.6K
May 29, 2026	6.74	7.09	6.68	6.68	1.01K
May 27, 2026	6.33	6.56	6.33	6.56	4.09K
May 26, 2026	6.90	6.90	6.90	6.90	173
May 22, 2026	6.53	6.53	6.40	6.40	1.31K
May 21, 2026	6.75	6.75	6.75	6.75	1.06K
May 20, 2026	6.92	6.92	6.92	6.92	7
May 19, 2026	5.98	6.62	5.98	6.62	406
May 15, 2026	6.84	6.84	6.84	6.84	678

Contact Details

Melbourne, VIC 3000

Australia

https://www.clinuvel.com 613 966 04900

About Company

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage. The company's development portfolio also features CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which stimulates extended cellular activity; and PRÉNUMBRA, an injectable liquid form of afamelanotide. Clinuvel Pharmaceuticals has forged a partnership with HK Winhealth Pharma Group Co. Limited to deliver SCENESSE to EPP patients in the People's Republic of China through a specialized named patient program. Established in 1987, the company maintains its principal office in Melbourne, Australia.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 ELOX

0.05+0.36%

Eloxx Pharmaceuticals, Inc.$13.98 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $5.98 and $9.00. With a market capitalization of about $371.02 million, Clinuvel Pharmaceuticals Limited is classified as a small-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 1.68 thousand shares, trading with heavier-than-usual volume. Headquartered in Melbourne, VIC, Clinuvel Pharmaceuticals Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Philippe Jacques Wolgen, the company employs approximately 100 people and listed since January 30, 2008. Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland.

Technical Performance

Average 10-day trading volume of 4.32 thousand shares is significantly above the 3-month average of 1.82 thousand, indicating heightened recent market interest.

Valuation Metrics

Clinuvel Pharmaceuticals Limited trades at a P/E ratio of 16.14, slightly below the S&P 500 average, with a price-to-sales ratio of 5.53 and a price-to-book ratio of 2.12 suggesting the stock is closer to book value. The P/FCF stands at 13.27, also above market averages.

Dividend & Fair Value

Clinuvel Pharmaceuticals Limited last paid a dividend of 0.03 per share, this equals a trailing yield of roughly 0.49%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $13.78. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Clinuvel Pharmaceuticals Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 25, 2026, missed forecasts by -25.9%. The prior quarter beat by 57.59%. Over the last six quarters, Apple has recorded several small beats. These include 23.83% in February 22, 2024.

Financial & Profitability Overview

Over the trailing twelve months, Clinuvel Pharmaceuticals generated $95.02M in revenue, or $1.89 per share. Gross margin was 83.29%, operating margin 48.13%, and net profit margin 38.07%. Returns are healthy, with ROA at 13.31% and ROE at 15.02%.
On valuation metrics, Clinuvel Pharmaceuticals trades at a P/E of 16.14, P/S of 5.53 and P/B of 2.12. The current ratio is 14.64 and quick ratio is 14.17. Operationally, the company’s inventory turnover is 4.12 and cash conversion cycle is 39.42 days. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of 118.09.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Clinuvel Pharmaceuticals posted revenue of $95.02M, down slightly from $88.18M in the prior quarter. Gross profit was $79.14M (margin 83.29%). Operating income was $45.73M (margin 48.1%). Net income was$36.17M (EPS $0.72).
The company ended the quarter with $224.11M in cash and short-term investments, a total debt of $528.53K, and net debt of - $223.58M. Total assets were $271.75M, with equity of $240.81M. Financials further reflected stability, with operating cash flow of $41.10M, free cash flow of $40.80M, and capital expenditures of - $298.57K.

Price Forecast & Outlook

Our AI price prediction model suggests that Clinuvel Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Clinuvel Pharmaceuticals Limited trading at a premium to the broader market with a P/E of 16.14.

Frequently Asked Questions

What is the current Clinuvel Pharmaceuticals Limited (CLVLY) stock price?

Clinuvel Pharmaceuticals Limited (OTC: CLVLY) stock price is $7.36 in the last trading session. During the trading session, CLVLY stock reached the peak price of $7.40 while $6.98 was the lowest point it dropped to. The percentage change in CLVLY stock occurred in the recent session was 0% while the dollar amount for the price change in CLVLY stock was $0.00.

CLVLY's industry and sector of operation?

The OTC listed CLVLY is part of Biotechnology industry that operates in the broader Healthcare sector. Clinuvel Pharmaceuticals Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CLVLY?

Mr. Darren M. Keamy
Chief Financial Officer & Company Sec.
Mr. Malcolm Bull
Head of Investor Relations
Mr. Lachlan Hay
Director of Global Operations
Dr. Dennis J. Wright
Chief Scientific Officer
Dr. Philippe Jacques Wolgen M.B.A., M.D., MBA
Chief Executive Officer, MD & Director

How CLVLY did perform over past 52-week?

CLVLY's closing price is 14.64% higher than its 52-week low of $5.98 where as its distance from 52-week high of $9.00 is -27.75%.

How many employees does CLVLY have?

Number of CLVLY employees currently stands at 100.

Link for CLVLY official website?

Official Website of CLVLY is: https://www.clinuvel.com

How do I contact CLVLY?

CLVLY could be contacted at phone 613 966 04900 and can also be accessed through its website. CLVLY operates from 535 Bourke Street, Melbourne, VIC 3000, Australia.

How many shares of CLVLY are traded daily?

CLVLY stock volume for the day was 3.77K shares. The average number of CLVLY shares traded daily for last 3 months was 1.68K.

What is the market cap of CLVLY currently?

The market value of CLVLY currently stands at $371.02M with its latest stock price at $7.36 and 50.41M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	100
Beta	0.61
Sales or Revenue	$95.02M
5Y Sales Change%	1.87%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

CLVLY Company Profile and Key Details

Clinuvel Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics